BRAF and cancer: B-Raf inhibitors, such as dabrafenib and vemurafenib, are used in the treatment of V600EB-Raf positive cancers, including metastatic melanoma and non-small-cell lung cancer [14–16] alone or in combination with a MEK1/2 inhibitor (trametinib).